Edition:
United States

Pharma Mar SA (PHMR.MC)

PHMR.MC on Madrid SE C.A.T.S.

2.30EUR
8 Dec 2017
Change (% chg)

€-0.02 (-0.86%)
Prev Close
€2.32
Open
€2.30
Day's High
€2.36
Day's Low
€2.30
Volume
387,954
Avg. Vol
703,641
52-wk High
€4.26
52-wk Low
€2.04

Latest Key Developments (Source: Significant Developments)

Pharma Mar says IDMC recommends Phase III trial with Zepsyre in small-cell lung cancer patients to continue
Wednesday, 15 Nov 2017 02:12am EST 

Nov 15 (Reuters) - PHARMA MAR SA ::PHASE III TRIAL WITH ZEPSYRE IN SMALL-CELL LUNG CANCER PATIENTS (ATLANTIS) TO CONTINUE WITHOUT CHANGES ON POSITIVE RECOMMENDATION BY IDMC (INDEPENDENT DATA MONITORING COMMITTEE).  Full Article

Pharma Mar presents positive results from phase II study of lurbinectedin in Ewing's sarcoma
Monday, 13 Nov 2017 02:22am EST 

Nov 13 (Reuters) - PHARMA MAR SA ::PRESENTS POSITIVE RESULTS FROM A PHASE II STUDY OF LURBINECTEDIN IN EWING´S SARCOMA.OBSERVED DISEASE CONTROL RATE AT 60 PERCENT, INCLUDING PARTIAL RESPONSES IN 12 PERCENT AND STABILIZATION IN 48 PERCENT OF CASES.‍​.  Full Article

Pharma Mar expects EMA not to approve its Aplidin for multiple myeloma treatment
Thursday, 9 Nov 2017 01:50am EST 

Nov 9 (Reuters) - PHARMA MAR SA ::SAID ON WEDNESDAY, EXPECTS AN OPINION RECOMMENDING AGAINST APPROVAL OF MARKETING AUTHORIZATION APPLICATION FOR APLIDIN FOR TREATMENT OF MULTIPLE MYELOMA FROM EUROPEAN MEDICINES AGENCY (EMA) BASED ON PRELIMINARY "TREND VOTE" FEEDBACK FROM AGENCY.FORMAL WRITTEN DECISION FROM EMA'S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) IS EXPECTED FOLLOWING ITS DECEMBER 2017 MEETING (DEC 11 TO DEC 15).COMPANY DEEPLY SURPRISED ABOUT CHMP NEGATIVE TREND VOTE GIVEN RESULTS OF PHASE III TRIAL.CHMP NEGATIVE TREND VOTE WAS VERBALLY COMMUNICATED TO COMPANY BY EMA.  Full Article

Pharma Mar and South Korea's Boryung Pharm sign licensing deal for Zepsyre
Tuesday, 7 Nov 2017 05:16am EST 

Nov 7 (Reuters) - PHARMA MAR SA ::SIGNS LICENSING AGREEMENT WITH BORYUNG PHARM TO COMMERCIALIZE THE MARINE-DERIVED ANTICANCER DRUG ZEPSYR (LURBINECTEDIN), IF APPROVED, IN SOUTH KOREA.TO RECEIVE A NON-DISCLOSED UPFRONT PAYMENT AND TO BE ELIGIBLE FOR ADDITIONAL REMUNERATIONS UPON ACHIEVING REGULATORY AND SALES MILESTONES.TO RETAIN EXCLUSIVE PRODUCTION RIGHTS AND TO SELL THE PRODUCT TO BORYUNG PHARM FOR COMMERCIAL USE.ZEPSYRE IS CURRENTLY IN LATE-STAGE CLINICAL DEVELOPMENT FOR PLATINUM-RESISTANT OVARIAN CANCER AND FOR SMALL-CELL LUNG CANCER.  Full Article

Pharma Mar 9-month net loss narrows to 14.5 mln euros YoY
Tuesday, 24 Oct 2017 11:42am EDT 

Oct 24 (Reuters) - PHARMA MAR SA ::9-MONTH REVENUE 140.4 MILLION EUROS VERSUS 139.6 MILLION EUROS YEAR AGO.9-MONTH NET LOSS 14.5 MILLION EUROS VERSUS LOSS 16.6 MILLION EUROS YEAR AGO.9-MONTH NEGATIVE EBITDA 4.6 MILLION EUROS VERSUS NEGATIVE 5.6 MILLION EUROS YEAR AGO.  Full Article

Pharma Mar submits MAA for Aplidin in Switzerland for multiple myeloma treatment
Wednesday, 4 Oct 2017 06:55am EDT 

Oct 4 (Reuters) - PHARMA MAR SA ::SUBMITS MARKETING AUTHORISATION APPLICATION (MAA) FOR APLIDIN IN SWITZERLAND FOR TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA.‍​.  Full Article

Pharma Mar presents response rate data with PM1183 in patients with lung cancer‍​
Tuesday, 12 Sep 2017 03:27am EDT 

Sept 12 (Reuters) - PHARMA MAR SA ::NEW POSITIVE DATA ON PM1183 SEES RESPONSE RATE OF 36 PERCENT AS SINGLE AGENT IN PATIENTS WITH ADVANCED AND RELAPSED SMALL-CELL LUNG CANCER.SAYS UP TO TODAY, THERE IS ONLY ONE APPROVED THERAPY, TOPOTECAN, IN RELAPSED DISEASE, THAT OFFERS A RESPONSE RATE OF BETWEEN 17 PERCENT AND 24 PERCENT.  Full Article

Pharma Mar unit presents positive results for lung cancer‍​ diagnostic kit
Monday, 11 Sep 2017 07:29am EDT 

Sept 11 (Reuters) - PHARMA MAR SA ::ITS UNIT GENOMICA PRESENTS POSITIVE RESULTS FOR ITS CLART CMA EGFR DIAGNOSTIC KIT FOR NON-SMALL CELL LUNG CANCER (NSCLC) FOR HOSPITAL USE‍​.SAYS PRESENTED DATA FOR DIAGNOSTIC KIT CONFIRMS SENSITIVITY OF 100 PERCENT AND SPECIFICITY OF 96.5 PERCENT.  Full Article

Pharma Mar starts study with Aplidin for treatment of multiple myeloma
Wednesday, 9 Aug 2017 05:07am EDT 

Aug 9 (Reuters) - PHARMA MAR SA ::STARTS A QUADRUPLE COMBINATION STUDY WITH APLIDIN FOR THE TREATMENT OF MULTIPLE MYELOMA.STUDY TO EVALUATE RECOMMENDED DOSE (RD), EFFICACY OF THE COMBINATION ALONG WITH THE SAFETY PROFILE.  Full Article

Pharma Mar H1 revenue up 5.2 pct YoY
Wednesday, 26 Jul 2017 12:32pm EDT 

July 26 (Reuters) - PHARMA MAR SA ::H1 NET LOSS 7.4 MILLION EUROS VERSUS LOSS 13.2 MILLION EUROS YEAR AGO.H1 SALES FLAT AT 88.7 MILLION EUROS VERSUS 88.7 MILLION EUROS YEAR AGO.H1 TOTAL REVENUE UP 5.2 PCT AT 96.9 MILLION EUROS VERSUS YEAR AGO.H1 NEGATIVE EBITDA 767,000 EUROS VERSUS NEGATIVE 5.6 MILLION EUROS YEAR AGO.  Full Article

BRIEF-Pharma Mar Presents Positive Phase III Trial Results Of Plitidepsin In Multiple Myeloma

* SAYS PRESENTS POSITIVE RESULTS OF ADMYRE PHASE III TRIAL OF PLITIDEPSIN IN MULTIPLE MYELOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)